|Mr. Yip Hang Lee||Exec. Chairman & CEO||N/A||N/A||1954|
|Mr. Sien Lup Chew||Chief Financial Officer||N/A||N/A||1963|
|Dr. Janakan Krishnarajah||COO & Chief Medical Officer||N/A||N/A||N/A|
|Dr. Iain Bruce Cook||Chief Scientist||N/A||N/A||1960|
|Mr. Wei Hsiung Lee ACIS||Joint Company Sec.||N/A||N/A||N/A|
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Australia and Singapore. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for major depressive disorder. The company also develops BnoX, a sublingual buprenorphine wafer for the management of acute and chronic moderate to severe pain; Wafesil, a sublingual sildenafil wafer for the treatment of male erectile dysfunction; Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, tremor, and chronic inflammation. In addition, it offers LumeniX for skin lightening; and WafeRest for the promotion of sleep. Further, the company promotes and markets nutritional and supplements products through pharmacies, as well as through online; develops and commercializes of nutraceutical products; and provides laboratory services. iX Biopharma Ltd. was founded in 2008 and is headquartered in Singapore.
iX Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.